¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©
¼¶±ð: ²©Ê¿
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-20   

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£©

µÚËľüÒ½´óѧ1998ÄêÃâÒßѧ£¨²©Ê¿£© oek #^:pF  
x Ty7lfSe  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© #nbn K  
1.Co-stimulators (or co-stimulating molecules) PC0HH  
2.NK-kB "B?R| Xg  
3.Immunoglobulin superfamily d}VALjXHX!  
4.antigen-presenting cell (APC) uDI}R]8~  
5.death domain zM\IKo_"  
6.CCR and CXCR G V=OKf#  
7.Lectin (or mitogen) ik1XGFy ?  
8.Clusters of differentiation, CD) <oZ(ng@X  
9.B7 family n{z8Ao%  
10.Cytotoxic T lymphocyte, CTL) IY0 3"  
11.IL-15 and IL-15 receptor (IL-15R) L1rA T  
12.MHC restriction PRZ8X{h  
13.Affinity-chromatography e$H|MdYIA  
14.Cyctosprin A, CsA a" ^#!G<+  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) t( wZiK}  
gu^_iU  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© |$Qp0vOA}  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 CH55K[{<  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ /G{&[X<4U  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ 5"$e=y/  
Y' 2-yB  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© O(WEgz  
L,E-z_<p  
ÃâÒßѧרҵ£º Z(l9>A7!  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ !~?W \b\:  
<=$rU232}  
Ïû»¯ÄÚ¿Æ£º 23)F-.C} j  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ yB 1I53E  
'_k>*trV  
ѪҺ²¡Ñ§×¨Òµ£º 4u@yJ?U  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
freekaobo¹Ù·½Î¢ÐŶ©ÔĺŠÕýÈ·´ð°¸:¿¼²©
°´"Ctrl+Enter"Ö±½ÓÌá½»